|
MTIF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.83819975802169E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.78250000818048E-09 |
| Normal-vs-Stage2 |
6.188300E-02 |
| Normal-vs-Stage3 |
3.11999981406075E-10 |
| Normal-vs-Stage4 |
5.24989995920322E-09 |
| Stage1-vs-Stage2 |
1.376170E-02 |
| Stage1-vs-Stage3 |
9.770000E-02 |
| Stage1-vs-Stage4 |
7.265600E-02 |
| Stage2-vs-Stage3 |
1.376420E-03 |
| Stage2-vs-Stage4 |
8.248300E-04 |
| Stage3-vs-Stage4 |
6.161400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.86850576414599E-12 |
| Normal-vs-AfricanAmerican |
1.202290E-04 |
| Normal-vs-Asian |
2.81410000002591E-06 |
| Caucasian-vs-AfricanAmerican |
7.219000E-01 |
| Caucasian-vs-Asian |
6.525200E-01 |
| AfricanAmerican-vs-Asian |
9.891000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.40130000048089E-07 |
| Normal-vs-Female |
6.74859945704043E-10 |
| Male-vs-Female |
6.085400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.95040000500791E-09 |
| Normal-vs-Age(41-60Yrs) |
1.15690013124947E-10 |
| Normal-vs-Age(61-80Yrs) |
8.1904000000077E-05 |
| Normal-vs-Age(81-100Yrs) |
2.655800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.310400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.845030E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.473200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.161500E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.516600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.576800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.899400E-03 |
| Classical-VS-Follicular |
2.021500E-03 |
| Classical-VS-Other |
7.336400E-01 |
| Classical-VS-Normal |
3.34259999679176E-08 |
| Tall-VS-Follicular |
1.81551999999252E-05 |
| Tall-VS-Other |
3.462800E-01 |
| Tall-VS-Normal |
8.25210011434763E-10 |
| Follicular-VS-Other |
2.375400E-01 |
| Follicular-VS-Normal |
2.821900E-02 |
| Other-VS-Normal |
1.205960E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.87429999485434E-08 |
| Normal-vs-N1 |
6.0402016721639E-11 |
| N0-vs-N1 |
4.303500E-03 |
|
|
